In a new study published in Nature Communications, Boston Children's Hospital researchers identified a new target responsible for scar formation in the bone marrow of patients with a type of blood cancer known as myelofibrosis. Combining traditional myelofibrosis therapy with drugs that block scar formation may be a more effective treatment for patients with the disease.